Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.
about
Developmental pharmacokinetics in pediatric populationsAgent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivityPharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: a review of the data and identification of knowledge gaps.A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.Extrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods.Real-time, aptamer-based tracking of circulating therapeutic agents in living animals.Clinical pharmacological studies in children: From exploratory towards confirmation driven methodology.A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.Paediatric pharmacokinetics: key considerations.The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysisA physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsOptimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.Optimizing drug development of anti-cancer drugs in children using modelling and simulation.Herb-drug interactions: challenges and opportunities for improved predictions.Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?Current toxicological aspects on drug and chemical transport and metabolism across the human placental barrier.Methods for pharmacokinetic analysis in young children.Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician's request for a more integrated approach.Evaluating parameter availability for physiologically based pharmacokinetic (PBPK) modeling of perfluorooctanoic acid (PFOA) in zebrafish.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Use of a semi-physiological pharmacokinetic model to investigate the influence of itraconazole on tacrolimus absorption, distribution and metabolism in mice.Individualizing the use of medications in children: making Goldilocks happy.Perinatal pharmacology.
P2860
Q27002933-C9794A35-38B8-407A-8C24-D9F537978550Q27028010-9FD5A99C-9F88-45AD-B22B-659833910427Q30841046-EF358333-B9B8-477A-BBFD-4020937C5674Q30985909-0E289312-525D-4C25-AF7B-6F90CB497DE7Q31060832-10B69EDF-FA4E-4F35-8F1E-A1C9C21C75E5Q33570021-1F34CF20-5C77-4C4C-9D93-493207987331Q34093287-00DC4951-E167-41EF-8BB9-81856404BB8CQ34570770-2B38F7EF-31D4-4768-BCA2-36507D1EEA60Q35135940-73F40CCF-8B17-4D6D-8F6B-BBA05FB6625FQ35998017-1AA9A40D-DBCF-4801-A973-097F5359CE0DQ36025902-00B1AEB0-4697-4785-A8F7-72E6BDDCD3F0Q36072504-FE5F254E-3975-46F2-A180-09A657E16A47Q36987975-F53F520B-B671-4CF9-9075-9F7EBD3A184EQ37603890-5BFF5242-006B-4E91-9A71-CB385CCBB82DQ37974113-5589217B-C40F-4C69-B1F9-B7E3162B22B2Q38025182-6A21D7A9-8B77-471E-A50E-20C4A35174E4Q38187157-6C33851A-E050-4A21-9627-38C165C2F19AQ38758820-B135A0B9-A937-44DA-9FBC-C70DA8C0E23AQ38893881-D2D7ADA5-EB7A-490A-9451-AA1A26AFC7FBQ38959281-199A32E5-97A4-4E66-AB56-1F78B93853E5Q41671785-908C02F6-6247-482A-9960-3C66B0880460Q41975490-77C4BD2D-226C-430B-8817-E73D5A5E6A7FQ42582591-1C0093B5-ECB1-4FD0-A984-8B9EC7939944Q47229635-D21ADC4D-48B8-4372-8FE7-A9928A8B5F38Q47592224-02E29F52-234A-487F-9326-966CFCEFECC1Q48566470-DDB5C1F0-0806-4175-A1C4-869D6EDF0CA5Q50655840-3048C51A-C6BD-46E0-8507-CC80872114B7Q55208168-179D79B5-B946-4D38-AE7B-D2FCDDB993DB
P2860
Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Physiologically based pharmaco ...... in pediatric drug development.
@ast
Physiologically based pharmaco ...... in pediatric drug development.
@en
type
label
Physiologically based pharmaco ...... in pediatric drug development.
@ast
Physiologically based pharmaco ...... in pediatric drug development.
@en
prefLabel
Physiologically based pharmaco ...... in pediatric drug development.
@ast
Physiologically based pharmaco ...... in pediatric drug development.
@en
P2860
P356
P1476
Physiologically based pharmaco ...... in pediatric drug development.
@en
P2093
Feras Khalil
Stephanie Läer
P2860
P304
P356
10.1155/2011/907461
P577
2011-06-01T00:00:00Z